Pamidronate Sodium and Calcitonin-Resistant Paget’s Disease: Immediate Response in a Patient

Sabra Drake, James D. Massie, Arnold E. Postlethwaite, Genaro M.A. Palmieri

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

One three-day course of intravenous pamidronate sodium (3-amino-1 -hydroxypropylidene-1,1-bisphosphonate), 30 mg/d, in a patient with calcitonin-resistant Paget’s disease resulted in the following: marked clinical improvement within two weeks; normalization of urinary hydroxyproline value; fall of serum alkaline phosphatase value (900 to 250 U/L); a rise in serum osteocalcin value by the tenth week that returned to pretreatment levels in the 16th week; transient hypocalcemia with elevation of parathyroid hormone value; reduction in urinary calcium excretion; and improvement in bone scans. No adverse reactions occurred, with the exception of mild and transient hyperpyrexia for 48 hours during pamidronate administration. White blood cell counts did not change and serum interleukin 1 was undetectable before and after treatment with pamidronate. Pamidronate seems to be highly effective in the treatment of Paget’s disease of the bone, but its profound effects on mineral and bone metabolism require close monitoring during the short-term period of intravenous treatment.

Original languageEnglish (US)
Pages (from-to)401-403
Number of pages3
JournalArchives of Internal Medicine
Volume149
Issue number2
DOIs
StatePublished - Feb 1989

Fingerprint

pamidronate
Calcitonin
Sodium
Serum
Osteitis Deformans
Bone and Bones
Hypocalcemia
Hydroxyproline
Osteocalcin
Parathyroid Hormone
Interleukin-1
Leukocyte Count
Minerals
Alkaline Phosphatase
Therapeutics
Calcium

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Pamidronate Sodium and Calcitonin-Resistant Paget’s Disease : Immediate Response in a Patient. / Drake, Sabra; Massie, James D.; Postlethwaite, Arnold E.; Palmieri, Genaro M.A.

In: Archives of Internal Medicine, Vol. 149, No. 2, 02.1989, p. 401-403.

Research output: Contribution to journalArticle

Drake, Sabra ; Massie, James D. ; Postlethwaite, Arnold E. ; Palmieri, Genaro M.A. / Pamidronate Sodium and Calcitonin-Resistant Paget’s Disease : Immediate Response in a Patient. In: Archives of Internal Medicine. 1989 ; Vol. 149, No. 2. pp. 401-403.
@article{2b9482a873c34c058245d4ee924b523e,
title = "Pamidronate Sodium and Calcitonin-Resistant Paget’s Disease: Immediate Response in a Patient",
abstract = "One three-day course of intravenous pamidronate sodium (3-amino-1 -hydroxypropylidene-1,1-bisphosphonate), 30 mg/d, in a patient with calcitonin-resistant Paget’s disease resulted in the following: marked clinical improvement within two weeks; normalization of urinary hydroxyproline value; fall of serum alkaline phosphatase value (900 to 250 U/L); a rise in serum osteocalcin value by the tenth week that returned to pretreatment levels in the 16th week; transient hypocalcemia with elevation of parathyroid hormone value; reduction in urinary calcium excretion; and improvement in bone scans. No adverse reactions occurred, with the exception of mild and transient hyperpyrexia for 48 hours during pamidronate administration. White blood cell counts did not change and serum interleukin 1 was undetectable before and after treatment with pamidronate. Pamidronate seems to be highly effective in the treatment of Paget’s disease of the bone, but its profound effects on mineral and bone metabolism require close monitoring during the short-term period of intravenous treatment.",
author = "Sabra Drake and Massie, {James D.} and Postlethwaite, {Arnold E.} and Palmieri, {Genaro M.A.}",
year = "1989",
month = "2",
doi = "10.1001/archinte.1989.00390020105022",
language = "English (US)",
volume = "149",
pages = "401--403",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Pamidronate Sodium and Calcitonin-Resistant Paget’s Disease

T2 - Immediate Response in a Patient

AU - Drake, Sabra

AU - Massie, James D.

AU - Postlethwaite, Arnold E.

AU - Palmieri, Genaro M.A.

PY - 1989/2

Y1 - 1989/2

N2 - One three-day course of intravenous pamidronate sodium (3-amino-1 -hydroxypropylidene-1,1-bisphosphonate), 30 mg/d, in a patient with calcitonin-resistant Paget’s disease resulted in the following: marked clinical improvement within two weeks; normalization of urinary hydroxyproline value; fall of serum alkaline phosphatase value (900 to 250 U/L); a rise in serum osteocalcin value by the tenth week that returned to pretreatment levels in the 16th week; transient hypocalcemia with elevation of parathyroid hormone value; reduction in urinary calcium excretion; and improvement in bone scans. No adverse reactions occurred, with the exception of mild and transient hyperpyrexia for 48 hours during pamidronate administration. White blood cell counts did not change and serum interleukin 1 was undetectable before and after treatment with pamidronate. Pamidronate seems to be highly effective in the treatment of Paget’s disease of the bone, but its profound effects on mineral and bone metabolism require close monitoring during the short-term period of intravenous treatment.

AB - One three-day course of intravenous pamidronate sodium (3-amino-1 -hydroxypropylidene-1,1-bisphosphonate), 30 mg/d, in a patient with calcitonin-resistant Paget’s disease resulted in the following: marked clinical improvement within two weeks; normalization of urinary hydroxyproline value; fall of serum alkaline phosphatase value (900 to 250 U/L); a rise in serum osteocalcin value by the tenth week that returned to pretreatment levels in the 16th week; transient hypocalcemia with elevation of parathyroid hormone value; reduction in urinary calcium excretion; and improvement in bone scans. No adverse reactions occurred, with the exception of mild and transient hyperpyrexia for 48 hours during pamidronate administration. White blood cell counts did not change and serum interleukin 1 was undetectable before and after treatment with pamidronate. Pamidronate seems to be highly effective in the treatment of Paget’s disease of the bone, but its profound effects on mineral and bone metabolism require close monitoring during the short-term period of intravenous treatment.

UR - http://www.scopus.com/inward/record.url?scp=0024546791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024546791&partnerID=8YFLogxK

U2 - 10.1001/archinte.1989.00390020105022

DO - 10.1001/archinte.1989.00390020105022

M3 - Article

C2 - 2783843

AN - SCOPUS:0024546791

VL - 149

SP - 401

EP - 403

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 2

ER -